Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal
摘要:
A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal
摘要:
A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
Compounds with growth hormone releasing properties
申请人:NOVO NORDISK A/S
公开号:EP1506969A1
公开(公告)日:2005-02-16
Compounds of the general formula I
and their use for treating medical disorders resulting from a deficiency in growth hormone.
通式 I 的化合物
以及它们在治疗因生长激素缺乏而引起的疾病方面的用途。
COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES
申请人:NOVO NORDISK A/S
公开号:EP1047709B1
公开(公告)日:2004-11-03
US6083908A
申请人:——
公开号:US6083908A
公开(公告)日:2000-07-04
[EN] COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES<br/>[FR] COMPOSES AVEC PROPRIETES DE LIBERATION DE L'HORMONE DE CROISSANCE
申请人:——
公开号:WO1999036431A9
公开(公告)日:2000-07-27
[EN] Compounds of general formula (I), and their use for treating medical disorders resulting from a deficiency in growth hormone. [FR] Cette invention se rapporte à des composés représentés par la formule générale (I), et à leur utilisation dans le traitement des affections médicales résultant d'une déficience de l'hormone de croissance.
Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal
A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.